解放军总医院第五医学中心2002年-2018年常见非感染性肝病构成比及变化趋势分析

何婷婷; 景婧; 柏兆方; 邹正升; 宋雪艾; 王伽伯; 肖小河

doi:10.3969/j.issn.1001-5256.2020.08.019

解放军总医院第五医学中心2002年-2018年常见非感染性肝病构成比及变化趋势分析

DOI: 10.3969/j.issn.1001-5256.2020.08.019

1. 解放军总医院第五医学中心中西医结合科
2. 解放军总医院第五医学中心中医科
3. 解放军总医院第五医学中心非感染性肝病诊疗中心
4. 全军中医药研究所

基金项目:

国家自然科学基金重点项目(81630100);国家自然科学基金创新群体项目(81721002)；国家重大新药创制科技重大专项课题(2015ZX09501-004-001-008)；国家公益性行业专项课题(201507004-04)；

详细信息

中图分类号: R575
计量
- 文章访问数: 1682
- HTML全文浏览量: 29
- PDF下载量: 146
- 被引次数: 0
出版历程
- 出版日期: 2020-08-20

Constituent ratio and changing trend of non-infectious liver diseases in The Fifth Medical Center of Chinese PLA General Hospital from 2002 to 2018

The Fifth Medical Center of Chinese PLA General Hospital

Research funding:

摘要

摘要:
目的对比分析住院的4种常见非感染性肝病住院患者2002年-2018年构成比及变化趋势。方法收集2002年-2018年解放军总医院第五医学中心收治的37 973例非感染性肝病患者[出院病历的病案首页第一诊断为酒精性肝病（n=14 971）、药物性肝损伤（药物性肝损害）（n=11 406）、非酒精性脂肪性肝病（n=1776）和自身免疫性肝病（n=9820）]的病历资料,包括年龄、性别分布特征并对变化趋势进行对比分析。计数资料组间比较采用χ2检验。结果药物性肝损伤患者占常见非感染肝病患者的30.04%,排在第2位,仅次于酒精性肝病。2011年以前药物性肝损伤患者占总住院肝病患者的比例呈上升趋势,2012年后该构成比开始呈一过性下降趋势。不同年龄段男女分布有显著差异（χ2=113.087,P<0.05）。男性发病年龄主要集中在40～49岁,女性主要集中在50～59岁。不同住院年份的药物性肝损伤男性和女性患者,在不同高发年龄段分布均存在显著差异（男性:χ2=369.252,P<0.001;女性:χ2
- 化学性与药物性肝损伤 /
- 肝疾病,酒精性 /
- 非酒精性脂肪性肝病
Abstract:
Objective To investigate the constituent ratio and changing trend of four common types of non-infectious liver diseases in our hospital from 2002 to 2018.Methods Medical records were collected from 37 973 patients with non-infectious liver diseases who were admitted to The Fifth Medical Center of Chinese PLA General Hospital from 2002 to 2018,and according to the first diagnosis listed in the first page of discharge medical records,14 971 patients had alcoholic liver disease,11 406 had drug-induced liver injury,1776 had nonalcoholic fatty liver disease,and 9820 had autoimmune liver diseases.The distribution characteristics of age and sex and the changing trend were analyzed.The chi-square test was used for comparison of categorical data between groups.Results The patients with drug-induced liver injury accounted for 30.04% of the patients with common non-infectious liver diseases,and it ranked only second to alcoholic liver diseases in all four types.The proportion of patients with drug-induced liver injury among the hospitalized patients with liver diseases tended to increase before 2011,and this constituent ratio showed a trend of transient reduction after 2012.There was a significant difference in sex distribution between the patients with different ages(χ2=113.087,P<0.05).The age of onset was mainly 40-49 years in male patients and50-59 years in female patients.There were significant differences in the age distribution of drug-induced liver injury between the male and female patients hospitalized in different years(χ2=369.252 and 663.490,both P<0.05).There was no significant change in the range of peak age of onset in male patients,while in female patients,the range of peak age of onset showed an aging trend from 40-49 years to50-59 years in the recent 6 years.Conclusion Drug-induced liver injury has become a major part of non-infectious liver disease and often occurs in middle-aged and elderly women.The prevention,control,diagnosis,and treatment of drug-induced liver injury should be taken seriously,especially medication guide and education for middle-aged and elderly women,and it is recommended to strengthen the monitoring of liver function during medication.
- chemical and drug induced liver injury /
- liver diseases,alcoholic /
- non-alcoholic fatty liver disease

HTML全文

参考文献(27)

[1] National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association;Fatty Liver Expert Committee,Chinese Medical Doctor Association. Guidelines of prevention and treatment for alcoholic liver disease:A 2018 update[J]. J Clin Hepatol,2018,34(5):939-946.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会．酒精性肝病防治指南(2018年更新版)[J]．临床肝胆病杂志，2018,34(5):939-946.

[2] DANAN G,BENICHOU C. Causality assessment of adverse reactions to drug-I. A novel method based on the conclusions of international consensus meetings:Application to drug-induced liver injury[J]. J Clin Epidemiol,1993,46(11):1323-1330.

[3] Drug-induced Liver Disease Study Group,Chinese Society of Hepatology,Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol,2015,31(11):1752-1769.(in Chinese)中华医学会肝病学分会药物性肝病学组．药物性肝损伤诊治指南[J]．临床肝胆病杂志，2015,31(11):1752-1769.

[4] Branch of Hepatobiliary Diseases,China Association of Chinese Medicine,Branch of Chinese Patent Medicine,China Association of Chinese Medicine. Guidelines for the clinical management of herb-induced liver injury[J]. J Clin Hepatol,2016,32(5):835-843.(in Chinese)中华中医药学会肝胆病分会，中华中医药学会中成药分会．中草药相关肝损伤临床诊疗指南[J]．临床肝胆病杂志，2016,32(5):835-843.

[5] National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association;Fatty Liver Expert Committee,Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:A 2018 update[J]. J Clin Hepatol,2018,34(5):947-957.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会．非酒精性脂肪性肝病防治指南(2018年更新版)[J]．临床肝胆病杂志，2018,34(5):947-957.

[6] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Infectious Diseases,Chinese Medical Association. Consensus on the diagnosis and management of autoimmune hepatitis(2015)[J]. J Clin Hepatol,2016,32(1):9-22.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会．自身免疫性肝炎诊断和治疗共识(2015)[J]．临床肝胆病杂志，2016,32(1):9-22.

[7] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Infectious Diseases,Chinese Medical Association. Consensus on the diagnosis and management of primary biliary cirrhosis(cholangitis)(2015)[J]. J Clin Hepatol,2015,31(12):1980-1988.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会．原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015)[J]．临床肝胆病杂志，2015,31(12):1980-1988.

[8] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Infectious Diseases,Chinese Medical Association. Consensus on the diagnosis and management of primary sclerosing cholangitis(2015)[J]. J Clin Hepatol,2016,32(1):23-31.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会．原发性硬化性胆管炎诊断和治疗专家共识(2015)[J]．临床肝胆病杂志，2016,32(1):23-31.

[9] Cooperative Group of Investigation of Alcohol Dependence and Related Issues. A collaborative study on alcohol dependence among the populations of 4 occupations in 9 cities of China:I.Methodology and prevalence rate[J]. Chin Mental Health J,1992,6(3):112-115,142.(in Chinese)酒精依赖与有关问题调查协作组．中国9个城市4种职业人群酒精依赖协作研究(一)方法学及患病率[J]．中国心理卫生杂志，1992,6(3):112-115,142.

[10] Cooperative Group of Investigation of Alcohol Dependence and Related Issues. A collaborative study on alcohol dependence among the populations of 4 occupations in 9 cities of China:II.Harm of alcohol dependence on mental,physical,and social functions[J]. Chin Mental Health J,1992,6(3):116-117,136.(in Chinese)酒精依赖与有关问题调查协作组．中国9个城市4种职业人群酒精依赖协作研究(二)酒精依赖对精神、躯体和社会功能的危害[J]．中国心理卫生杂志，1992,6(3):116-117,136.

[11] CHEN SL,MENG XD,WANG BY,et al. An epidemiologic survey of alcoholic liver disease in some cities of Liaoning Province(2010)[J]. J Prac Hepatol,2010,13(6):428-435.(in Chinese)陈士林，孟晓丹，王炳元，等．辽宁省部分城市酒精性肝病流行现状调查[J]．实用肝脏病杂志，2010,13(6):428-430,435.

[12] WANG H,MA L,YIN Q,et al. Prevalence of alcoholic liver disease and its association with socioeconomic status in north-eastern China[J]. Alcohol Clin Exp Res,2014,38(4):1035-1041.

[13] HUANG SL,DAI SQ,ZHANG XH,et al. An epidemiological investigation of alcoholic liver disease in Hunan Province,China[J]. J Chin Physician,2005,7(3):426-427.(in Chinese)黄顺玲，戴水奇，张雪红，等．湖南省酒精性肝病流行病学调查概况[J]．中国医师杂志，2005,7(3):426-427.

[14] LIU JJ,JIAO Y,ZHANG HP. An epidemiological investigation of alcoholic liver disease[J]. J Mod Med Health,2010,26(10):1590-1591.(in Chinese)刘江静，焦洋，张宏萍．酒精性肝病的流行病学调查[J]．现代医药卫生，2010,26(10):1590-1591.

[15] LU XL,TAO M,LUO JY,et al. Epidemiology of alcoholic liver diseases in Xi’an[J]. World Chin J Dig,2003,11(6):719-722.(in Chinese)鲁晓岚，陶明，罗金燕，等．西安酒精性肝病流行病学[J]．世界华人消化杂志，2003,11(6):719-722.

[16] National Cooperative Group of Alcoholic Liver Disease Investigation. Management of malignant biliary hilar obstruction with multiple stents[J]. Chin J Dig,2007,27(4):231-234.(in Chinese)全国酒精性肝病调查协作组．全国酒精性肝病的多中心调查分析[J]．中华消化杂志，2007,27(4):231-234.

[17] SHEN T,LIU Y,SHANG J,et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology,2019,156(8):2230-2241.

[18] NAVARRO VJ,BARNHART HX,BONKOVSKY HL,et al. 167herbal and dietary supplement induced hepatotoxicity in the U. S.[J]. Gastroenterology,2012,142(5):S-41.

[19] AKEMI T,YASUNI N,KOUICHI T,et al. Comparison of liver biopsy findings with the digestive disease week Japan 2004scale for diagnosis of drug-induced liver injury[J]. Mediators Inflamm,2015,2015:1-9.

[20] CHALASANI N,HAYASHI P,BONKOVSKY H,et al. ACG Clinical Guideline:The diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol,2014,109(7):950-966,quiz 967.

[21] Chinese Society of Tuberculosis,Chinese Medical Association.Expert recommendations on the diagnosis and treatment of liver injury induced by antitubercular agents[J]. Chin J Tuberc Respir Dis,2013,36(10):732-736.(in Chinese)中华医学会结核病学分会．抗结核药所致药物性肝损伤诊断与处理专家建议[J]．中华结核和呼吸杂志，2013,36(10):732-736.

[22] LI YJ,QI H,SHEN C,et al. Research advances in susceptibility to hepatotoxicity induced by antitubercular agents[J]. Chin J Evid Based Pediatr,2016,11(4):309-316.(in Chinese)李颖佳，綦辉，申晨，等．抗结核药物致肝毒性易感性研究进展[J]．中国循证儿科杂志，2016,11(4):309-316.

[23] WANG JY,TSAI CH,LEE YL,et al. Gender-dimorphic impact of PXR Genotype and haplotype on hepatotoxicity during antituberculosis treatment[J]. Medicine(Baltimore),2015,94(24):e982.

[24] ZHU JZ,ZHOU QY,WANG YM,et al. Prevalence of fatty liver disease and the economy in China:A systematic review[J].World J Gastroenterol,2015,21(18):5695-5706.

[25] LEUNG JC,LOONG TC,WEI JL,et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients[J]. Hepatology,2017,65(1):54-64.

[26] WANG Y,WANG B,SHEN F,et al. Body mass index and risk of primary liver cancer:A meta-analysis of prospective studies[J]. Oncologist,2012,17(11):1461-1468.

[27] WONG VW,WONG GL,YEUNG JC,et al. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram:A prospective cohort study[J]. Hepatology,2016,63(3):754-763.

施引文献

资源附件(0)

访问统计